3D1015 Injection for Advanced Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This Phase 1 trial tests a new injectable treatment called 3D1015 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to target cancer cells using a special imaging marker that shows up on PET scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man, age 18 or older, with prostate cancer confirmed by biopsy
- Your testosterone has been lowered to castrate levels (through medication or surgery)
- A special PET scan (68Ga-PSMA) shows your cancer cells light up
- Your cancer has spread to other parts of your body and is no longer responding to previous treatments
- You have adequate organ function (kidneys, liver, heart) to safely receive the treatment
- Any side effects from past cancer treatments have resolved to mild-moderate level
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination that uses a radioactive molecule to find and treat prostate cancer cells that have spread and are no longer responding to hormone therapy. It may be an option for men with a specific protein called PSMA on their cancer cells.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
Hear when a new Metastatic Castration-resistant Prostate Cancer, mCRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.